从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素

doi:10.3969/j.issn.1672-5069.2015.02.032

摘要/Abstract

摘要： 肝硬化患者门静脉血栓(PVT)的发生率明显高于健康人群。门静脉血栓形成会影响患者预后。Virchow三要素(血液高凝状态、血管内皮损伤、血流速度减慢)是经典的血栓形成理论。肝硬化患者脾功能亢进、肝功能下降导致与出凝血相关的血液成分发生变化,肝纤维化压迫肝内血管,硬化剂治疗、腹部手术、感染、内毒素血症等损伤血管内皮,压迫或药物原因导致门静脉血流受阻等均可以是门静脉血栓形成的危险因素。本文主要从Virchow三要素角度入手,描述与肝硬化患者PVT形成相关的危险因素,为制定准确预测PVT发生的方法,预防和治疗PVT提供理论依据。

关键词: 肝硬化, 门静脉血栓, 危险因素, Virchow三要素

Abstract: Portal vein thrombosis （PVT） is more common in cirrhotic patients than in normal people, which may have adverse effect on prognosis of patients with liver cirrhosis.Virchow’s triad（hypercoagulability,vascular endothelial injury and reduced blood flow velocity） is a classic theory about thrombosis. Hypersplenism and liver dysfunction cause the change of clotting factors,and intrahepatic vascular compress by liver fibrosis,sclerotherapy,abdominal surgery,infection as well as endotoxemia may injure the endothelial cells;Portal hypertension or prophylactic medicine may block the blood flow. All of the above factors can be the risk factors of PVT. This review mainly describes the risk factors of PVT in cirrhotic patients from the view of Virchow’s triad and hopes to provide theoretical basis for the formulation of prediction method,prevention and treatment of PVT.

Key words: Liver cirrhosis, Portal vein thrombosis, Risk factors, Virchow’s triad

李玲, 陈世耀. 从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素[J]. 实用肝脏病杂志, 2015, 18(3): 325-328.

Li Ling, Chen Shiyao. Risk factors of portal vein thrombosis in cirrhotic patients from the view of Virchow’s triad[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 325-328.

参考文献

[1] Rajani R,Bjornsson E,Bergquist A,et al. The epidemiology and clinical features of portal vein thrombosis：a multicentre study.Aliment Pharmacol Ther,2010,32：1154-1162.
[2] Okuda K,Ohnishi K,Kimura K,et al.Incidence of portal vein thrombosis in liver cirrhosis：An angiographic study in 708 patients.Gastroenterology,1985,89：279-286.
[3] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40：736-741.
[4] Francoz C,Belghiti J,Vilgrain V,et al.Splanchnic vein thrombosis in candidates for liver transplantation：usefulness of screening and anticoagulation.Gut,2005,54（5）：691-697.
[5] Tsochatzis EA,Senzolo M,Germani G,et al. Systematic review：portal vein thrombosis in cirrhosis.Aliment Pharmacol Ther,2010,31：366-374.
[6] Ponziani FR1,Zocco MA,Garcovich M,et al.What we should know about portal vein thrombosis in cirrhotic patients：A changing perspective.World J Gastroenterol,2012,18（36）：5014-5020.
[7] Ferreira CN,Rodrigues T,Alexandrino P,et al.Portal vein thrombosis in cirrhotic patients is associated with advanced liver disease and predicts poor long term prognosis. Hepatology,2010,52：1072A.
[8] Hodge A,Crispiny P.Coagulopathy in liver disease：The whole is greater than the sum of its parts. J Gastroenterol Hepatol,2010,25（1）：1-2.
[9] Li MX,Zhang XF,Liu ZW,et al. Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis.Hepatobiliary Pancreat Dis Int,2013,12（5）：512-519.
[10] 梅斌,郑凯,陈孝平.断流术后门静脉血栓形成与血小板膜蛋CD62P的关系. 华中科技大学学报（医学版）,2006,35（4）：548-549.
[11] Martinelli I,Primignani M,Aghemo A,et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol,2009,50：916-922.
[12] Zocco MA,Di Stasio E,De Cristofaro R,et al.Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development. J Hepatol,2009,51（4）：682-689.
[13] Bombeli T,Basic A,Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems.Am J Hematol,2002,70：126-132.
[14] Zhang D,Hao JY,Yang N. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis.J Gastroenterol Hepatol,2010,25（1）：116-121.
[15] Rossetto V,Spiezia L,Senzolo M,et al. Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis.Int J Lab Hematol,2013,35（1）：101-105.
[16] Mangia A,Villani MR,Cappucci G,et al.Causes of portal venous thrombosis in cirrhotic patients：the role of genetic and acquired factors. Eur J Gastroenterol Hepatol,2005,17（7）：745-751.
[17] Amitrano L,Brancaccio V,Guardascione MA,et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients:Role of genetic thrombophilia. Endoscopy,2002,34（7）：535-538.
[18] Politoske D,Ralls P,Korula J.Portal vein thrombosis following endoscopic variceal sclerotherapy：Prospective controlled comparison in patients with cirrhosis.Dig Dis Sci,1996,41：185-190.
[19] Violi F,Ferro D,Basili S,et al.Ongoing prothrombotic state in the portal circulation of cirrhotic patients.Thromb Haemost,1997,77：44-47.
[20] Merkel C,Sacerdoti D,Bolognesi M,et al. Doppler sonography and hepatic vein catheterization in portal hypertension：assessment of agreement in evaluating severity and response to treatment. J Hepatol,1998,28（4）：622-630.
[21] Bolognesi M,Sacerdoti D,Mescoli C,et al.Different hemodynamic patterns of alcoholic and viral endstage cirrhosis：analysis of explanted liver weight,,degree of fibrosis and splanchnic Doppler parameters.Scand J Gastroenterol,2007,42：256-262.
[22] 胡培欣.卡维地洛对肝硬化患者肝静脉压力梯度及门静脉系统血流动力学影响. 山东大学2011年硕士论文:321.
[23] 刘君.心得安对肝硬化患者门静脉系统血流动力学及Tei指数的影响. 河北医科大学2009年硕士论文:213.
[24] Ayala R,Grande S,Bustelos R,et al. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. BMC Gastroenterol,2012,12：114.
[25] Amitrano L,Brancaccio V,Guardascione MA,et al.Inherited coagulation disorders in cirrhotic patients with portal thrombosis.Hepatology,2000,31（2）：345-348.
[26] Gabr MA,Bessa SS,El-Zamarani EA.Portal vein thrombosis in Egyptian patients with liver cirrhosis：Role of methylenetetrahydrofolate reductase C677T gene mutation.Hepatol Res,2010,40（5）：486-493.
[27] Erkan O,Bozdayi AM,Disibeyaz S,et al.Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis.Eur J Gastroenterol Hepatol,2005,17（3）：339-343.
[28] Amitrano L,Guardascione MA,Brancaccio V,et al.Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40（5）：736-741.
[29] Saugel B,Lee M,Feichtinger S,et al.Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis. J Thromb Thrombolysis,2014 Aug 14.[Epub ahead of print]
[30] Primignani M,Martinelli I,Bucciarelli P,et al.Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology,2005,41（3）：603-608.
[31] 卢翔,赵青川,韩国宏,等. 肝硬化门静脉高压症术后门静脉血栓形成危险因素研究. 中国实用外科杂志,2013,33（3）:215-218.
[32] Northup PG,McMahon MM,Ruhl AP,et al.Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol,2006,101（7）：1524-1528. quiz 1680.
[33] Ogren M,Bergqvist D,Bjorck M,et al.Portal vein thrombosis：prevalence,patient characteristics and lifetime risk：a population study based on 23,796 consecutive autopsies.World J Gastroenterol,2006,12（13）：2115-2119.
[34] Fimognari FL,De Santis A,Piccheri C,et al.Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med,2005,146（4）：238-243.
[35] Girleanu I,Trifan A,Cojocariu C,et al.The risk of thrombotic events in patients with liver cirrhosis. Rev Med Chir Soc Med Nat Iasi,2012,116（4）：991-996.